Mon, Mar 17, 8:46 PM (34 days ago)
### Summary of Quanterix Corporation (QTRX) Annual Report (2024) **Financial Performance:** - **Revenue:** $137.4 million (2024) vs. $122.4 million (2023), a 12% increase. - **Net Loss:** $38.5 million (2024) vs. $28.4 million (2023), a 36% increase. - **Gross Profit:** $83.1 million (2024) vs. $74.2 million (2023), a 12% increase. - **Operating Expenses:** $135.7 million (2024) vs. $120.2 million (2023), a 13% increase. **Revenue Breakdown:** - **Product Revenue:** $79.7 million (2024) vs. $79.7 million (2023). - **Service and Other Revenue:** $51.2 million (2024) vs. $40.1 million (2023), a 28% increase. - **Collaboration and License Revenue:** $4.5 million (2024) vs. $1.4 million (2023), a 223% increase. - **Grant Revenue:** $2.0 million (2024) vs. $1.2 million (2023), a 62% increase. **Operating Expenses Breakdown:** - **Research and Development:** $31.1 million (2024) vs. $26.1 million (2023), a 19% increase. - **Selling, General, and Administrative:** $101.6 million (2024) vs. $89.1 million (2023), a 14% increase. - **Other Lease Costs:** $3.0 million (2024) vs. $3.7 million (2023), a 19% decrease. - **Impairment and Restructuring:** $0 (2024) vs. $1.3 million (2023). **Strategic Overview:** - **Acquisitions:** Acquired Emission, Inc. and agreed to acquire Akoya Biosciences, Inc. - **Product Launches:** Launched LucentAD Complete, a confirmatory blood biomarker test for Alzheimer’s disease. - **ISO 13485 Certification:** Achieved ISO 13485 certification for operations in Billerica, Massachusetts. **Future Outlook:** - **Simoa ONE:** Expected launch by the end of 2025, aiming for a 10-fold increase in sensitivity. - **Market Position:** Focus on neurology, oncology, and immunology indications. - **Financial Condition:** Cash and cash equivalents of $56.7 million and marketable securities of $232.4 million as of December 31, 2024. **Risk Factors:** - **Operational Risks:** Dependence on key suppliers and contract manufacturers. - **Regulatory Risks:** Potential changes in FDA regulations and international regulatory requirements. - **Financial Risks:** Dependence on grant funding and potential fluctuations in revenue. **Market Position Changes:** - **Competitive Landscape:** Faces competition from established and development-stage life science companies. - **Product Adoption:** Continued focus on expanding the installed base of Simoa instruments and increasing consumables revenue.